Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on February 15, 2008, detailing the approval and issuance of retention awards to key members of its Executive Committee. These awards, granted on February 12, 2008, are designed to retain senior management during a critical period for the company. The compensation structure allows executives to choose between stock options, deferred stock units (DSUs), and cash, with all components subject to a two-year vesting or payment schedule. The primary objective of these awards is to ensure stability and continued leadership within the executive ranks, which is particularly important given the 'challenging but critical period' mentioned in the filing. Investors should note that these grants are a strategic move to mitigate leadership attrition and maintain operational focus amidst potential uncertainties. The specific amounts and types of awards vary per executive, reflecting their roles and responsibilities.
Key Highlights
- 1Boston Scientific (BSX) issued retention awards to members of its Executive Committee on February 12, 2008.
- 2The awards are intended to retain key senior management personnel during a critical company period.
- 3Executives could choose among stock options, deferred stock units (DSUs), and cash as forms of retention award.
- 4All awarded stock options and DSUs are subject to a two-year ratable vesting schedule.
- 5Cash retention awards are also paid out ratably over a two-year period.
- 6The Compensation Committee approved these awards to address retention concerns.
- 7Specific award details vary by executive, including James Gilbert, David McFaul, Lucia Quinn, Fredericus Colen, Stephen Moreci, Kenneth Pucel, William McConnell, Paul Donovan, William Kucheman, and Brian Burns.